[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HUP0300709A2 - Pemetrexedet monotioglikollal, L-ciszteinnel vagy tioglikolsavval együtt tartalmazó gyógyászati készítmény - Google Patents

Pemetrexedet monotioglikollal, L-ciszteinnel vagy tioglikolsavval együtt tartalmazó gyógyászati készítmény

Info

Publication number
HUP0300709A2
HUP0300709A2 HU0300709A HUP0300709A HUP0300709A2 HU P0300709 A2 HUP0300709 A2 HU P0300709A2 HU 0300709 A HU0300709 A HU 0300709A HU P0300709 A HUP0300709 A HU P0300709A HU P0300709 A2 HUP0300709 A2 HU P0300709A2
Authority
HU
Hungary
Prior art keywords
thioglycolic acid
monothiaglycerol
cystein
pharmaceutical composition
pemetrexed
Prior art date
Application number
HU0300709A
Other languages
English (en)
Inventor
Jens Kemken
Bernd Ulrich Riebesehl
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0002691A external-priority patent/GB2358799A/en
Priority claimed from GB0019599A external-priority patent/GB2365768A/en
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of HUP0300709A2 publication Critical patent/HUP0300709A2/hu
Publication of HUP0300709A3 publication Critical patent/HUP0300709A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

A találmány tárgyát különösen egy olyam gyógyászati készítmény képezi,amely pemetrexedet; legalább egy antioxidánst, amely monotioglicerol,L-cisztein vagy tioglikolsav lehet; és egy gyógyászatilag elfogadhatósegédanyagot tartalmaz. A találmány szerinti vegyületek rák kezelésérealkalmasak. Ó
HU0300709A 2000-02-04 2001-01-23 Pharmaceutical composition comprising pemetrexed together with monothiaglycerol l-cystein or thioglycolic acid HUP0300709A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0002691A GB2358799A (en) 2000-02-04 2000-02-04 A pharmaceutical composition comprising pemetrexed and an antioxidant
GB0019599A GB2365768A (en) 2000-08-09 2000-08-09 Stable liquid composition containing pemetrexed
PCT/US2001/000648 WO2001056575A1 (en) 2000-02-04 2001-01-23 Pharmaceutical composition comprising pemetrexed together with monothioglycerol l-cystein or thioglycolic acid

Publications (2)

Publication Number Publication Date
HUP0300709A2 true HUP0300709A2 (hu) 2003-07-28
HUP0300709A3 HUP0300709A3 (en) 2005-04-28

Family

ID=26243579

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0300709A HUP0300709A3 (en) 2000-02-04 2001-01-23 Pharmaceutical composition comprising pemetrexed together with monothiaglycerol l-cystein or thioglycolic acid

Country Status (31)

Country Link
EP (1) EP1265612B1 (hu)
JP (1) JP2003521518A (hu)
KR (1) KR20020081293A (hu)
CN (1) CN1396828A (hu)
AR (1) AR027360A1 (hu)
AT (1) ATE267601T1 (hu)
AU (1) AU3442201A (hu)
BR (1) BR0107958A (hu)
CA (1) CA2399124A1 (hu)
CO (1) CO5280222A1 (hu)
CZ (1) CZ20022654A3 (hu)
DE (1) DE60103512T2 (hu)
DK (1) DK1265612T3 (hu)
DZ (1) DZ3269A1 (hu)
EA (1) EA004708B1 (hu)
ES (1) ES2220716T3 (hu)
HK (1) HK1052461A1 (hu)
HR (1) HRP20020636A2 (hu)
HU (1) HUP0300709A3 (hu)
IL (1) IL150475A0 (hu)
MX (1) MXPA02007191A (hu)
MY (1) MY129450A (hu)
NO (1) NO20023379L (hu)
NZ (1) NZ519727A (hu)
PE (1) PE20011223A1 (hu)
PL (1) PL356705A1 (hu)
PT (1) PT1265612E (hu)
SK (1) SK10982002A3 (hu)
SV (1) SV2002000301A (hu)
TR (1) TR200401436T4 (hu)
WO (1) WO2001056575A1 (hu)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003057153A2 (en) * 2001-12-28 2003-07-17 Guilford Pharmaceuticals, Inc. Aqueous based pharmaceutical formulations of water-soluble prodrugs of propofol
KR101069128B1 (ko) * 2011-03-10 2011-09-30 건일제약 주식회사 페메트렉시드 또는 그의 염을 포함하는 항산화제-비함유 주사용 용액 형태의 약학적 제제의 제조방법
KR20130122065A (ko) * 2012-04-30 2013-11-07 씨제이제일제당 (주) 페메트렉시드를 함유하는 안정화된 주사용 액상 제제
EP2666463A1 (en) 2012-05-21 2013-11-27 Synthon BV Stabilized liquid composition comprising pemetrexed
DE102012010774A1 (de) * 2012-05-31 2013-12-05 Stada Arzneimittel Ag Pharmazeutische Pemetrexed-Lösung
KR101260636B1 (ko) 2012-11-29 2013-05-13 씨제이제일제당 (주) 안정화된 페메트렉시드 제제
KR101485243B1 (ko) * 2013-05-08 2015-01-21 씨제이헬스케어 주식회사 안정화된 페메트렉시드 제제
JP6094388B2 (ja) * 2013-06-07 2017-03-15 ニプロ株式会社 ペメトレキセドを含む注射用組成物
CN103340826B (zh) * 2013-07-05 2015-09-09 浙江震元制药有限公司 美他多辛注射用组合物及其制备方法
DK3040074T3 (en) 2013-10-03 2018-10-08 Fujifilm Corp INJECTION PREPARATION AND METHOD OF PREPARING IT
KR101703980B1 (ko) 2013-12-30 2017-02-08 주식회사 삼양바이오팜 항산화제를 함유하지 않는 약학 조성물 및 그의 제조방법
WO2015145911A1 (ja) * 2014-03-28 2015-10-01 富士フイルム株式会社 注射液製剤及びその製造方法
WO2016024369A1 (ja) * 2014-08-13 2016-02-18 テバ製薬株式会社 がん治療用医薬組成物
SI3206666T1 (sl) 2014-10-16 2020-04-30 Synthon B.V. Tekoč farmacevtski sestavek, ki obsega pemetreksed
KR101770605B1 (ko) * 2014-11-17 2017-08-23 동아에스티 주식회사 페메트렉시드 또는 그것의 약제학적으로 허용가능 한 염을 함유하는 안정한 약제학적 조성물
KR101919436B1 (ko) * 2015-05-28 2018-11-16 주식회사 삼양바이오팜 안정화된 약학 조성물 및 그의 제조방법
KR101693675B1 (ko) * 2015-12-14 2017-01-06 주식회사 종근당 페메트렉시드 또는 그의 약제학적으로 허용가능한 염을 함유하는 안정화된 약학조성물
US20170239250A1 (en) 2016-02-19 2017-08-24 Eagle Pharmaceuticals, Inc. Pemetrexed formulations
JP2019094284A (ja) * 2017-11-21 2019-06-20 日本化薬株式会社 ペメトレキセドを含有する注射用溶液製剤

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0162654B1 (ko) * 1989-12-11 1998-11-16 알렌 제이. 시니스갤리 N-(피롤로[2,3-d]피리미딘-3-일아크릴)-글루타민산 유도체

Also Published As

Publication number Publication date
CZ20022654A3 (cs) 2003-01-15
EA004708B1 (ru) 2004-06-24
IL150475A0 (en) 2002-12-01
DZ3269A1 (fr) 2001-08-09
AU3442201A (en) 2001-08-14
PE20011223A1 (es) 2001-12-20
ES2220716T3 (es) 2004-12-16
DE60103512T2 (de) 2005-06-02
HRP20020636A2 (en) 2003-10-31
DK1265612T3 (da) 2004-08-09
CA2399124A1 (en) 2001-08-09
DE60103512D1 (de) 2004-07-01
EP1265612B1 (en) 2004-05-26
JP2003521518A (ja) 2003-07-15
MY129450A (en) 2007-04-30
CN1396828A (zh) 2003-02-12
HUP0300709A3 (en) 2005-04-28
SK10982002A3 (sk) 2003-03-04
EP1265612A1 (en) 2002-12-18
MXPA02007191A (es) 2002-12-09
KR20020081293A (ko) 2002-10-26
TR200401436T4 (tr) 2004-07-21
SV2002000301A (es) 2002-06-07
NO20023379D0 (no) 2002-07-12
NO20023379L (no) 2002-09-30
EA200200831A1 (ru) 2003-02-27
BR0107958A (pt) 2002-10-29
WO2001056575A1 (en) 2001-08-09
PL356705A1 (en) 2004-06-28
NZ519727A (en) 2004-04-30
HK1052461A1 (en) 2003-09-19
AR027360A1 (es) 2003-03-26
PT1265612E (pt) 2004-08-31
ATE267601T1 (de) 2004-06-15
CO5280222A1 (es) 2003-05-30

Similar Documents

Publication Publication Date Title
HUP0300709A2 (hu) Pemetrexedet monotioglikollal, L-ciszteinnel vagy tioglikolsavval együtt tartalmazó gyógyászati készítmény
IL154888A (en) Aqueous Pharmaceutical Gel Preparation Containing At least One Vitamin D or One Vitamin D Analog At least One Corticosteroid
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
SE0001899D0 (sv) New compounds
EP1819227A4 (en) PHARMACEUTICAL FORMULATION OF DECITABINE
MXPA04004842A (es) Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1.
MXPA04004837A (es) Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1.
NO324227B1 (no) Cyclopropyl-kondenserte pyrrolidin-baserte forbindelser, farmasoytiske blandinger og kombinasjoner inneholdende slike samt anvendelse av slike for fremstilling av medikamenter for behandling av sykdommer
SG158870A1 (en) Bendamustine pharmaceutical compositions for lyophilisation
TW200716157A (en) Pharmaceutical formulations and methods of treatment using the same
WO2004030611A3 (en) Non-nucleoside reverse transcriptase inhibitors
BRPI0206509B8 (pt) processo para formular, para administração parenteral, um análogo de epotilona, preparação farmacêutica, processo para formar uma composição farmacêutica para administração parental, composição farmacêutica e uso de um análogo de epotilona na preparação de uma composição farmacêutica para o tratamento de câncer
UA94036C2 (ru) Фармацевтическая композиция бендамустина, предназначенная для лиофилизации
WO2004045557A3 (en) Novel lapachone compounds and methods of use thereof
AU9678501A (en) Pharmaceutical solutions of modafinil compounds
MY148125A (en) Compounds
RS44204A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
RS44304A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
EP1778209B8 (en) Methods and compositions for oral delivery of fts
HUP0402654A2 (hu) 2-[(2'-Halogén-3',5'-dialkoxi-fenil)-imino]-imidazolidin-származékok, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
WO2003080568A3 (en) Probucol derivatives
DE602004022578D1 (de) Antitumorale terpen-verbindungen
BR0213463A (pt) Composições farmacêuticas contendo macrólidos
GB0128071D0 (en) Medicament
RS20060435A (en) Compostions comprising glycosaminoglycan and nonsteroidal anti-inflammatory drug

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees